Clinical Trials Browser

Phase 2 × OTHER × lorlatinib × Clear all

NCT07415005 2026-05-05

Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung Cancer

Phase 2 Recruiting

Advanced Non-Small Cell Lung Cancer

NCT05740943 2026-01-20

Induction Lorlatinib in Stage III Non-small Cell Lung Cancer

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04621188 2025-09-24

Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS)

Phase 2 Active not recruiting

Non Small Cell Lung Cancer Metastatic

NCT07083687 2025-07-24

Lorlatinib in ROS1+ NSCLC With Brain Metastasis

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04111705 2025-04-01

ORAKLE

Phase 2 Completed

Non Small Cell Lung Cancer Metastatic

NCT06682884 2024-11-12

NEOLORA

Phase 2 Not yet recruiting

Neoadjuvant Non-Small Cell Lung Cancer

NCT04322890 2024-10-22

PIKACHU

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT05014464 2024-09-20

ATPase

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06378892 2024-04-23

ALK-PPL

Phase 2 Recruiting

Non Small Cell Lung Cancer Metastatic

NCT02925234 2024-01-24

DRUP

Phase 2 Recruiting

Neoplasms

NCT05948462 2023-12-13

NSCLC

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

NCT06092086 2023-10-23

Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLC

Phase 2 Recruiting

ALK Positive Non-small Cell Lung Cancer

NCT03505554 2023-08-07

CRU3

Phase 2 Unknown

Recurrence, Lymphoma, Large-Cell, Anaplastic

NCT03439215 2021-07-19

PFROST

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT02927340 2021-03-09

A Study of Lorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Measurable Extracranial Lesions

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms